Targeted Delivery of Mesenchymal Stem Cell-Derived Bioinspired Exosome-Mimetic Nanovesicles with Platelet Membrane Fusion for Atherosclerotic Treatment

References

• Wang D, Yang Y, Lei Y, et al. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products. Pharmacol Rev. 2019;71(4):596–670. doi:10.1124/pr.118.017178
   PubMed Web of Science ®Google Scholar
• Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124(10):1505–1518. doi:10.1161/CIRCRESAHA.119.312617
   PubMed Web of Science ®Google Scholar
• Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013;424:245–252. doi:10.1016/j.cca.2013.06.006
   PubMed Web of Science ®Google Scholar
• Zhang J, Zu Y, Dhanasekara CS, et al. Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9:1.
   Web of Science ®Google Scholar
• Zi Y, Yang K, He J, Wu Z, Liu J, Zhang W. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev. 2022;188:114449. doi:10.1016/j.addr.2022.114449
   PubMed Web of Science ®Google Scholar
• Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020;157:142–160. doi:10.1016/j.addr.2020.06.005
   PubMed Web of Science ®Google Scholar
• Pillai SC, Borah A, Le MNT, Kawano H, Hasegawa K, Kumar DS. Co-delivery of curcumin and Bioperine via PLGA nanoparticles to prevent atherosclerotic foam cell formation. Pharmaceutics. 2021;13:9.
   Web of Science ®Google Scholar
• Mu D, Wang X, Wang H, et al. Chemiexcited photodynamic therapy integrated in polymeric nanoparticles capable of MRI against atherosclerosis. Int J Nanomed. 2022;17:2353–2366. doi:10.2147/IJN.S355790
   PubMed Web of Science ®Google Scholar
• Esfandyari-Manesh M, Abdi M, Talasaz AH, Ebrahimi SM, Atyabi F, Dinarvand R. S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques. Daru. 2020;28(1):131–138. doi:10.1007/s40199-019-00324-w
   PubMed Web of Science ®Google Scholar
• Gao C, Liu C, Chen Q, et al. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis. J Control Release. 2022;349:2–15. doi:10.1016/j.jconrel.2022.06.053
   PubMed Web of Science ®Google Scholar
• Dhanasekara CS, Zhang J, Nie S, Li G, Fan Z, Wang S. Nanoparticles target intimal macrophages in atherosclerotic lesions. Nanomedicine. 2021;32:102346. doi:10.1016/j.nano.2020.102346
   PubMed Web of Science ®Google Scholar
• Pham LM, Kim EC, Ou W, et al. Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis. Biomaterials. 2021;269:120677. doi:10.1016/j.biomaterials.2021.120677
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–149. doi:10.2147/ijn.s596
   PubMed Web of Science ®Google Scholar
• Zhen X, Cheng P, Pu K. Recent Advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small. 2019;15(1):e1804105. doi:10.1002/smll.201804105
   PubMed Web of Science ®Google Scholar
• Gao M, Liang C, Song X, et al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater. 2017;29:35.
   Web of Science ®Google Scholar
• Wang Y, Zhang K, Qin X, et al. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management. Adv Sci. 2019;6(12):1900172. doi:10.1002/advs.201900172
   Web of Science ®Google Scholar
• Mehta S, Bongcaron V, Nguyen TK, et al. An ultrasound-responsive theranostic cyclodextrin-loaded nanoparticle for multimodal imaging and therapy for atherosclerosis. Small. 2022;18(31):e2200967. doi:10.1002/smll.202200967
   PubMed Web of Science ®Google Scholar
• Kim M, Sahu A, Hwang Y, et al. Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in Apo E(-/-) mice. Biomaterials. 2020;226:119550. doi:10.1016/j.biomaterials.2019.119550
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Dong Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283–4293. doi:10.1021/acs.accounts.1c00550
   PubMed Web of Science ®Google Scholar
• Goutas D, Pergaris A, Goutas N, Theocharis S. Utilizing exosomal-EPHs/ephrins as biomarkers and as a potential platform for targeted delivery of therapeutic exosomes. Int J Mol Sci. 2022;23:7.
   Web of Science ®Google Scholar
• Brezgin S, Parodi A, Kostyusheva A, et al. Technological aspects of manufacturing and analytical control of biological nanoparticles. Biotechnol Adv. 2023;64:108122. doi:10.1016/j.biotechadv.2023.108122
   PubMed Web of Science ®Google Scholar
• Yang W, Yin R, Zhu X, et al. Mesenchymal stem-cell-derived exosomal miR-145 inhibits atherosclerosis by targeting JAM-A. Mol Ther Nucleic Acids. 2021;23:119–131. doi:10.1016/j.omtn.2020.10.037
   PubMedGoogle Scholar
• Xing X, Li Z, Yang X, et al. Adipose-derived mesenchymal stem cells-derived exosome-mediated microRNA-342-5p protects endothelial cells against atherosclerosis. Aging. 2020;12(4):3880–3898. doi:10.18632/aging.102857
   PubMedGoogle Scholar
• Zhang N, Luo Y, Zhang H, Zhang F, Gao X, Shao J. Exosomes derived from mesenchymal stem cells ameliorate the progression of Atherosclerosis in ApoE(-/-) Mice via FENDRR. Cardiovasc Toxicol. 2022;22(6):528–544. doi:10.1007/s12012-022-09736-8
   PubMed Web of Science ®Google Scholar
• Safari S, Malekvandfard F, Babashah S, Alizadehasl A, Sadeghizadeh M, Motavaf M. Mesenchymal stem cell-derived exosomes: a novel potential therapeutic avenue for cardiac regeneration. Cell Mol Biol. 2016;62(7):66–73.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi:10.1038/ncb1596
   PubMed Web of Science ®Google Scholar
• Pan Y, Wu W, Jiang X, Liu Y. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: from mechanisms to therapy. Biomed Pharmacother. 2023;163:114817. doi:10.1016/j.biopha.2023.114817
   PubMed Web of Science ®Google Scholar
• Zou D, Yang P, Liu J, et al. Exosome-Loaded Pro-efferocytic Vascular Stent with Lp-PLA(2)-Triggered Release for Preventing In-Stent Restenosis. ACS Nano. 2022;16(9):14925–14941. doi:10.1021/acsnano.2c05847
   PubMed Web of Science ®Google Scholar
• Sun L, He X, Zhang T, Han Y, Tao G. Knockdown of mesenchymal stem cell‑derived exosomal LOC100129516 suppresses the symptoms of atherosclerosis via upregulation of the PPARgamma/LXRalpha/ABCA1 signaling pathway. Int J Mol Med. 2021;48:6.
   Web of Science ®Google Scholar
• Ma J, Chen L, Zhu X, Li Q, Hu L, Li H. Mesenchymal stem cell-derived exosomal miR-21a-5p promotes M2 macrophage polarization and reduces macrophage infiltration to attenuate atherosclerosis. Acta Biochim Biophys Sin. 2021;53(9):1227–1236. doi:10.1093/abbs/gmab102
   Google Scholar
• Li J, Xue H, Li T, et al. Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE(-/-) mice via miR-let7 mediated infiltration and polarization of M2 macrophage. Biochem Biophys Res Commun. 2019;510(4):565–572. doi:10.1016/j.bbrc.2019.02.005
   PubMed Web of Science ®Google Scholar
• Yoon J, Jo W, Jeong D, Kim J, Jeong H, Park J. Generation of nanovesicles with sliced cellular membrane fragments for exogenous material delivery. Biomaterials. 2015;59:12–20. doi:10.1016/j.biomaterials.2015.04.028
   PubMed Web of Science ®Google Scholar
• Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63–78. doi:10.1016/j.pharmthera.2017.02.020
   PubMed Web of Science ®Google Scholar
• Wiklander OP, Nordin JZ, O’Loughlin A, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4:26316. doi:10.3402/jev.v4.26316
   PubMed Web of Science ®Google Scholar
• Lai CP, Mardini O, Ericsson M, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014;8(1):483–494. doi:10.1021/nn404945r
   PubMed Web of Science ®Google Scholar
• Lee JR, Kyung JW, Kumar H, et al. Targeted delivery of mesenchymal stem cell-derived nanovesicles for spinal cord injury treatment. Int J Mol Sci. 2020;21:11.
   Web of Science ®Google Scholar
• Cao L, Tian T, Huang Y, et al. Neural progenitor cell-derived nanovesicles promote hair follicle growth via miR-100. J Nanobiotechnology. 2021;19(1):20. doi:10.1186/s12951-020-00757-5
   PubMed Web of Science ®Google Scholar
• Lee JR, Park BW, Kim J, et al. Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair. Sci Adv. 2020;6(18):eaaz0952. doi:10.1126/sciadv.aaz0952
   PubMed Web of Science ®Google Scholar
• Jo W, Jeong D, Kim J, Park J. Self-renewal of bone marrow stem cells by nanovesicles engineered from embryonic stem cells. Adv Healthc Mater. 2016;5(24):3148–3156. doi:10.1002/adhm.201600810
   PubMed Web of Science ®Google Scholar
• Oh K, Kim SR, Kim DK, et al. In vivo differentiation of therapeutic insulin-producing cells from bone marrow cells via extracellular vesicle-mimetic nanovesicles. ACS Nano. 2015;9(12):11718–11727. doi:10.1021/acsnano.5b02997
   PubMed Web of Science ®Google Scholar
• Jo W, Kim J, Yoon J, et al. Large-scale generation of cell-derived nanovesicles. Nanoscale. 2014;6(20):12056–12064. doi:10.1039/c4nr02391a
   PubMed Web of Science ®Google Scholar
• Jang SC, Kim OY, Yoon CM, et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. 2013;7(9):7698–7710. doi:10.1021/nn402232g
   PubMed Web of Science ®Google Scholar
• Choo YW, Kang M, Kim HY, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano. 2018;12(9):8977–8993. doi:10.1021/acsnano.8b02446
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Ha J, Lee M. Brain-targeted exosome-mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti-tumor effects in glioblastoma animal models. Bioeng Transl Med. 2023;8(2):e10426. doi:10.1002/btm2.10426
   PubMed Web of Science ®Google Scholar
• Modery-Pawlowski CL, Kuo HH, Baldwin WM, Sen Gupta A. A platelet-inspired paradigm for nanomedicine targeted to multiple diseases. Nanomedicine. 2013;8(10):1709–1727. doi:10.2217/nnm.13.113
   PubMed Web of Science ®Google Scholar
• Yin M, Lin J, Yang M, et al. Platelet membrane-cloaked selenium/ginsenoside Rb1 nanosystem as biomimetic reactor for atherosclerosis therapy. Colloids Surf B Biointerfaces. 2022;214:112464. doi:10.1016/j.colsurfb.2022.112464
   PubMed Web of Science ®Google Scholar
• Song Y, Huang Z, Liu X, et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE(-/-)) mice. Nanomedicine. 2019;15(1):13–24. doi:10.1016/j.nano.2018.08.002
   PubMed Web of Science ®Google Scholar
• Banskota S, Yousefpour P, Chilkoti A. Cell-based biohybrid drug delivery systems: the best of the synthetic and natural worlds. Macromol Biosci. 2017;17:1.
   Web of Science ®Google Scholar
• Fang RH, Jiang Y, Fang JC, Zhang L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials. 2017;128:69–83. doi:10.1016/j.biomaterials.2017.02.041
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release. 2015;220(Pt B):600–607. doi:10.1016/j.jconrel.2015.07.019
   PubMed Web of Science ®Google Scholar
• Klyachko NL, Arzt CJ, Li SM, Gololobova OA, Batrakova EV. Extracellular vesicle-based therapeutics: preclinical and clinical investigations. Pharmaceutics. 2020;12:12.
   Web of Science ®Google Scholar
• Huang HC, Wang TY, Rousseau J, et al. Lesion-specific suppression of YAP/TAZ by biomimetic nanodrug ameliorates atherosclerosis development. bioRxiv. 2023. doi:10.1101/2023.04.24.537992
   Google Scholar
• Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118–121. doi:10.1038/nature15373
   PubMed Web of Science ®Google Scholar
• Dehaini D, Wei X, Fang RH, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017;29:16.
   Web of Science ®Google Scholar
• Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043–7050. doi:10.1002/adma.201503323
   PubMed Web of Science ®Google Scholar
• Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104(3):932–936. doi:10.1073/pnas.0610298104
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Modery-Pawlowski CL, Menegatti S, et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano. 2014;8(11):11243–11253. doi:10.1021/nn503732m
   PubMed Web of Science ®Google Scholar
• Wei X, Gao J, Fang RH, et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials. 2016;111:116–123. doi:10.1016/j.biomaterials.2016.10.003
   PubMed Web of Science ®Google Scholar
• Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004;14(1):18–22. doi:10.1016/j.tcm.2003.09.007
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378–3384. doi:10.1172/JCI27196
   PubMed Web of Science ®Google Scholar
• Chen J, Lopez JA. Interactions of platelets with subendothelium and endothelium. Microcirculation. 2005;12(3):235–246. doi:10.1080/10739680590925484
   PubMed Web of Science ®Google Scholar
• Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276(6):618–632. doi:10.1111/joim.12296
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Kirkby NS, Chan MV, et al. Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood. 2015;126(10):e11–8. doi:10.1182/blood-2015-01-621656
   PubMed Web of Science ®Google Scholar
• Coenen DM, Mastenbroek TG, Cosemans J. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017;130(26):2819–2828. doi:10.1182/blood-2017-04-780825
   PubMed Web of Science ®Google Scholar
• Kim HY, Kumar H, Jo MJ, et al. Therapeutic Efficacy-potentiated and diseased organ-targeting nanovesicles derived from mesenchymal stem cells for spinal cord injury treatment. Nano Lett. 2018;18(8):4965–4975. doi:10.1021/acs.nanolett.8b01816
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589
   PubMed Web of Science ®Google Scholar
• Li G, Gu HM, Zhang DW. ATP-binding cassette transporters and cholesterol translocation. IUBMB Life. 2013;65(6):505–512. doi:10.1002/iub.1165
   PubMedGoogle Scholar
• Singaraja RR, Van Eck M, Bissada N, et al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 2006;114(12):1301–1309. doi:10.1161/CIRCULATIONAHA.106.621433
   PubMed Web of Science ®Google Scholar
• Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110(1):35–42. doi:10.1172/JCI15748
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004;101(26):9774–9779. doi:10.1073/pnas.0403506101
   PubMed Web of Science ®Google Scholar
• Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem. 2005;280(34):30150–30157. doi:10.1074/jbc.M505368200
   PubMed Web of Science ®Google Scholar
• Wang Y, Dubland JA, Allahverdian S, et al. Smooth muscle cells contribute the majority of foam cells in ApoE (Apolipoprotein E)-deficient mouse atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(5):876–887. doi:10.1161/ATVBAHA.119.312434
   PubMed Web of Science ®Google Scholar
• Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014;129(15):1551–1559. doi:10.1161/CIRCULATIONAHA.113.005015
   PubMed Web of Science ®Google Scholar
• Ma Y, Ma Y, Gao M, et al. Platelet-mimicking therapeutic system for noninvasive mitigation of the progression of atherosclerotic plaques. Adv Sci. 2021;8(8):2004128. doi:10.1002/advs.202004128
   Web of Science ®Google Scholar
• Chen L, Zhou Z, Hu C, et al. Platelet membrane-coated nanocarriers targeting plaques to deliver anti-CD47 antibody for atherosclerotic therapy. Research. 2022;2022:9845459. doi:10.34133/2022/9845459
   PubMedGoogle Scholar
• Wu G, Zhang J, Zhao Q, et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew Chem Int Ed Engl. 2020;59(10):4068–4074. doi:10.1002/anie.201913700
   PubMed Web of Science ®Google Scholar